Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

SEATTLE, April 4, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma (April 2011; 52(4): 620–628) published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone ("CPOP") in treating patients with aggressive non-Hodgkin's lymphoma ("NHL") who relapsed following initial therapy with cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone ("CHOP").  In the CPOP regimen, pixantrone substitutes for doxorubicin (H) in the CHOP regimen.  Peter Borchmann, M.D., of the University Hospital of Cologne, led the study.  CPOP produced high rates of complete remissions ("CR") and overall response rate ("ORR").  In some patients, these remissions were highly durable despite patients having relapsed after receiving CHOP and other multi-agent therapies.  

The study enrolled 35 patients in the phase I portion of the trial and 30 patients in the phase II portion of the trial. A major tumor response was reported for 80% and 73% of patients in phase I and II respectively, with 57% and 47% of the patients achieving a complete or unconfirmed CR. Median overall survival in the phase II portion of the trial was 17.9 months with four patients achieving notable long-term disease-free survival ranging from 55 to 77 months, despite in some cases having failed multiple prior regimens including stem cell transplantation. High response rates were also observed in the 43% of patients who had received prior rituximab as part of their front-line regimen (CHOP-R), with an ORR rate of 77% and CR rate of 54%. Myelosuppression was the most common toxicity. Side effects (grade 3/4) in phase I of the trial included febrile neutropenia (11%), grade 3/4 infections (3%), and cardiac failure (6%). In phase II of the trial, side effects (grade 3/4) included febril
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... company, today scheduled a conference call to discuss its ... 2013, ended April 30, 2013. The call will be ... The Company will report financial results for the second ... on Thursday, May 30, 2013. (Logo: ...
(Date:5/23/2013)... , May 23, 2013 More than ... may not benefit from chemotherapy and still have excellent ... launch of one of the largest sources of online ... website and interactive Facebook page provide recently diagnosed women ... can safely avoid chemotherapy. "We anticipate these ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3
... Nov. 4, 2010 Decision Resources, one of the ... healthcare issues, finds that biosimilar erosion of branded erythropoietin ... more rapid and more complete in the United States ... ESAs entered the European market in 2007. According to ...
... 4, 2010 NuView Life Sciences, Inc ("NuView"), ... proprietary target specific biomarkers for utilization with Positron ... its applications for the Qualifying Therapeutic Discovery Project ... The grants totaling just over $1.2 million dollars ...
Cached Medicine Technology:Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe 2NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010 2
(Date:5/24/2013)... Coral Springs, FL (PRWEB) May 24, 2013 ... to present May air dates for Charlotte, North Carolina. It ... home to many Fortune 500 companies. The city is populated ... top-notch healthcare organizations which cover residents in both North and ... program about all things medically-related can tune into WAXN-TV 64 ...
(Date:5/24/2013)... GA (PRWEB) May 24, 2013 CBT News.com ... Sales. Gonter joins the web-based retail automotive industry news organization ... , “I’m excited to join a group that’s so ... perfect example of how online video content is on the ... in the motorcycle business and segued into advertising at Cycle ...
(Date:5/24/2013)... Electric™ Energy Straws, an exciting new brand of ... and will be the lead sponsor on Munoz’s Chevy #26 ... Speedway. Munoz, who is part of Andretti Autosports’ fantastic five ... race, qualifying to be named the 2013 Indy 500 Fastest ... race. , While Munoz is grabbing headlines around the ...
(Date:5/24/2013)... American International College of Arts and ... agreement with Old Dominion University (ODU) that ... , The program will permit ODU students ... cell biology course, taught by AICASA’s faculty, for three ... of Antigua (AUA) College of Medicine , students will ...
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... range of products used outside the central laboratory, ... by a healthcare practitioner or by consumers. This ... coagulation, fertility and pregnancy, infectious and cardiovascular disease ... areas such as critical care, surgical and emergency ...
Breaking Medicine News(10 mins):Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 3Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3
... Practice Manager Notes Ease of Use, Time Savings, ... Healthcare, Inc. has,announced that West Michigan Orthopaedics, a ... is moving to the Intergy by Sage,practice management ... The three-physician group had been on The ...
... PARK, N.C., Dec. 11 Quintiles,Transnational Corp. today ... President and General Counsel., Previously Senior Vice ... Quintiles in 1998 as Vice President, European,Legal Affairs., ... and the clinical,research industry, having served the company ...
... Influenza Vaccination Into the New Year, BETHESDA, ... season,in full swing, getting vaccinated against influenza, commonly ... keep you and your family healthy. Too many,people ... in October and,November, but the National Foundation for ...
... Dec. 11 Amedica Corporation, an,orthopedic implants company ... the U.S. Food and Drug Administration,has granted a ... spinal implant., The Valeo VBR spinal implant ... surgical correction and stabilization of the thoracolumbar spine.,The ...
... Advance(R) and Similac(R) Isomil(R) Advance(R) Formulas Now ... Available in Nipple-Ready 8-Fluid-Ounce Bottles, COLUMBUS, Ohio, Dec. ... moms commissioned by Abbott,s Similac brand, packing the,diaper bag ... 30 minutes.,Nearly all moms surveyed (98 percent) agree that ...
... cells (progenitor cells) to treat the damage to cardiac ... Emory University School of Medicine. , The study investigators--Emory ... update their colleagues on its progress at the American ... "This is one of the first trials where patients ...
Cached Medicine News:Health News:West Michigan Orthopaedics Migrates to Intergy by Sage Practice Management System 2Health News:West Michigan Orthopaedics Migrates to Intergy by Sage Practice Management System 3Health News:Don't Let Influenza Ruin Your Holidays - Get Vaccinated 2Health News:Don't Let Influenza Ruin Your Holidays - Get Vaccinated 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:Similac(R) Survey Finds New Moms Want Convenient, Time-Saving Baby Products 2Health News:Similac(R) Survey Finds New Moms Want Convenient, Time-Saving Baby Products 3Health News:Adult stem cell heart attack study updated at American Society for Hematology Meeting 2
... H-1200 Fast Flow Fluid Warmer, a new generation ... the existing Level 1 Fast Flow Fluid Warmer ... Fluid Warmer incorporates the features of integrated air ... deliver warm fluids as fast as 1,000 ml/minute ...
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
... Flexible excellence for patients and clinicians., ... the Aestiva/5 anesthesia system, the Aestiva/5 MRI ... anesthesia systems with a fully functional, integrated ... (300 Gauss, 1.5 T active shielded magnet), ...
... meeting today's and tomorrow's needs in anesthesia procedures., ... solutions in its field today. This compact system ... revolving arm holds the complete user interface. A ... that there is less need to move the ...
Medicine Products: